Skip to main content
Premium Trial:

Request an Annual Quote

Burrill, Infinity Partner to Explore Life Science Opps in China

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life science venture capital and private equity firm Burrill & Co. and the Infinity Group today announced a joint venture to pursue life science investment opportunities in China.

Under the agreement, the two companies will co-invest into life science opportunities in China in US dollars and in renminbi, the currency of mainland China. Burrill, headquartered in San Francisco, will establish headquarters in Hong Kong for its China operations. Infinity already has a presence in Hong Kong, the two firms said in a joint statement.

Burrill will also use Infinity's 10 offices in China and its international offices in the US, Europe and Asia. In return, the partnership allows Infinity to strengthen its presence in the US, as part of its strategy to increase its presence as a global life science fund "bringing innovative technologies from Israel, the US, and Europe to China," the two companies said.

Based in Israel, Infinity describes itself on its website as "the world's leading cross-border Chinese focused management group" and manages more than $1 billion RMB and $700 million through 10 funds, including eight in China.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.